Clinical Trials on Stage IIIB Non-Small Cell Lung Cancer in China

Total 1930 results

Peking University
Merck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of... and other collaborators

Recruiting

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIB(N2) Non-small Cell Lung Cancer

China
Clifford Hospital, Guangzhou, China

Completed

Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer (VCONSCLC)

Carcinoma, Non-Small-Cell Lung | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
Alexander Chi

Not yet recruiting

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage II

China
Akeso

Completed

A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Hunan Province Tumor Hospital

Completed

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
Sichuan Cancer Hospital and Research Institute

Recruiting

Dose-painting Radiation for LA-NSCLC (DPRLC)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Stage II-IIIB(N2) Non-small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC (DYNAPET)

Non-small Cell Lung Cancer Stage III | PET/CT | Non-small Cell Lung Cancer Stage II

China
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Zhejiang Cancer Hospital

Unknown

Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection (ZTOG-1202)

Non-small Cell Lung Cancer Stage IIIA

China
The First Hospital of Jilin University

Active, not recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)

IIIA Stage Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Ruijin Hospital

Recruiting

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Sun Yat-sen University

Recruiting

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small Cell Lung Cancer

China
Anhui Provincial Cancer Hospital

Not yet recruiting

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Guangdong Provincial People's Hospital
Shenzhen University

Recruiting

Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC

Stage III Non-small Cell Lung Cancer

China
Xiangya Hospital of Central South University

Active, not recruiting

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC

Non-small Cell Lung Cancer Stage III

China
West China Hospital

Active, not recruiting

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Non-small Cell Lung Cancer | Stage III

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Puerto Rico
First People's Hospital of Hangzhou

Not yet recruiting

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Juan LI, MD

Recruiting

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Stage III Non-small Cell Lung Cancer

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Stage III

China
Zhejiang Cancer Hospital
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Stage III Non-small-Cell Lung Cancer

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
Sun Yat-sen University

Active, not recruiting

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small-cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
Shanghai Chest Hospital

Unknown

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC (HCFCCUSN)

Unresectable Stage III Non-small-cell Lung Cancer

China
Fudan University

Recruiting

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Immunotherapy | Stage II-IIIA

China
Hebei Medical University Fourth Hospital

Unknown

Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection (S1VSNP)

Non-small Cell Lung Cancer Stage ⅢA | Non-small Cell Lung Cancer Stage Ⅱ

China
Shanghai Chest Hospital
Fudan University; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaborators

Unknown

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (EFLRWR)

NSCLC Stage IV | NSCLC Stage IIIB | ALK Positive

China
Shanghai Chest Hospital

Unknown

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam
Chinese Lung Cancer Surgical Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Chinese PLA... and other collaborators

Unknown

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Non-small Cell Lung Cancer Stage IIIA

China
Tianjin Medical University Cancer Institute and...
Roche Pharma AG

Unknown

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer Stage III

China

Clinical Trials on Stage IIIB Non-Small Cell Lung Cancer in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations